The city of Scottsdale, Arizona, currently has 4 active clinical trials seeking participants for COPD research studies.
Pulmonary Rehabilitation for Rural Patients With COPD
Recruiting
The purpose of this study is to test the uptake, effectiveness, and patient-caregiver-provider experience of a crucial treatment not provided in rural areas: pulmonary rehabilitation.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Chronic Obstructive Pulmonary Disease (COPD
Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation
Recruiting
To evaluate the safety and effectiveness of the Automatic Expiratory Positive Airway Pressure (Auto-EPAP) feature versus manual expiratory positive airway pressure (EPAP) in the Vivo 45 LS Ventilator.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Insomnia and Sleep Institute of Arizona, LLC, Scottsdale, Arizona
Conditions: Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Diseases (NMD)
SPIROMICS Study of Early COPD Progression (SOURCE)
Recruiting
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: * To use CT scan imaging to identify which smokers will develop COPD. * To identify biomarkers predictive of smokers that will develop COPD. * To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study rela... Read More
Gender:
ALL
Ages:
Between 30 years and 55 years
Trial Updated:
02/20/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: COPD, Early-Onset
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: Honor Health, Scottsdale, Arizona
Conditions: COPD